SEQENS

OUR SCIENCE FOR YOUR FUTURE

Drug Delivery Solutions



Segens overview

Seqens is a worldwide leader in the development and production of active ingredients, pharmaceutical intermediates, specialty ingredients and cosmetics & personal care leveraging 24 manufacturing sites, 10 R&D centers and 3,200 employees in 10 countries.

As an integrated player across the value chain - from raw materials to active ingredients and from research and development to industrialization - Seqens offers a broad portfolio of active ingredients, pharmaceutical intermediates and specialty ingredients, develops and industrializes the most demanding molecules, and relies on its ability to innovate, develop and implement the best available technologies.

Driven not only by a culture of excellence and a strong entrepreneurial spirit, but also strong values such as unity, agility, and reactivity, our employees are committed to providing the highest level of service and quality to more than 1000 customers around the world while acting ethically in accordance to our strong Environmental, Social, and Governance program.



3200 people



300 scientists, experts and engineers



I() R&D centers



clients in more than 80 countries



24
manufacturing
sites

Seqens is a major vertically integrated pharma solutions actor offering a wide range of products and services from Solvents to Custom APIs

Pharmaceutical Solutions

Custom APIs

Intermediates

Drug Delivery solutions Lipids and Polymers

Generics

Consumer Healthcare

Life Science Inputs

Specialty Ingredients

Electronics

Cosmetics & Personal Care

Custom & Specialties


Lubricant Additives

Upstream Platform

Upstream assets to support the growth of small molecules, specialty ingredients and Life Science Inputs activities as a vertical integration platform

Sequens Pharmaceutical Solutions, leader in catalog and custom drug substances

With 25 years of experience in process development, scale-up and ongoing cGMP manufacturing of drug substances, we support emerging, specialty and large pharmaceutical customers for their drug substance or drug delivery needs.



Continuum in geographical coverage

- R&D centers in EU and US
- Manufacturing sites across 3 continents
- · Global network of sales offices
- Solutions for dual sourcing

Continuum in human regulatory

- Chemistry, Manufacturing and Controls
- Complementary chemistry and chemical engineering expertise for process industrialization
- Process safety
- Seqens'LAB, a unique Center of Excellence and dynamic multidisciplinary ecosystem dedicated to innovation and development

Foster growth with Seqens

Four companies – PCAS in France and Finland, Chemie Uetikon in Germany, PCI Synthesis in the United States and Wavelength in Israel & India – have joined forces as Seqens Pharmaceutical Solutions to offer world-class drug substance development and manufacturing services to the pharmaceutical industry.

Assets & Competencies



8 cGMP/FDA inspected sites WW



1,000 m³ 600 m³ cGMP



Pre-GMP sites for RSMs & Building-blocks



200+ DMFs for commercial drug substances



Over 35 years of drug substances production experience



In-house back integration of intermediates and starting materials for safe supply



Global sales and distribution network



Excellent regulatory compliance track record at all GMP sites



7 R&D Centers worldwide

A wide range of technologies

- High Pressure Reaction
- Low temperature technology
- Enzymatic Chemistry
- Potent API capabilities: OEL<100 ng/m³
- · API for injectable and ophthalmic FDF
- Controlled Substances
- Flow Chemistry
- Micronisation & spray drying services
- · Lipids & Polymer Synthesis

An international network

Benefit from a manufacturing network of **7 cGMP** plants located in Europe and the United States with a strong **regulatory track record** with international health authorities and the best **workshop & expertise in specialized technologies**



Drug Delivery Solutions for Bioavailability and Material for Medical Devices

SEQENS provides key expertise and capabilities in Drug Delivery Solutions for:

- RNA/DNA vectorization for the vaccines, oncology, etc.
- Materials for medical devices
- Bioavailability improvement (controlled-release, solubility enhancer, liposome)

Our Drug Delivery Solutions offer

CUSTOM LIPIDS

custom Synthesis of Lipids
as Drug delivery system for
RNA/DNA vaccines, gene
therapy, or liposome
vectorization of APIs

CUSTOM POLYMERS

Custom synthesis of **GMP** polymers: bioresorbable (PLA/PLGA, PCL) and hydrosoluble polymers like PEG, PEI, etc.

SMART EXCIPIENTS & CATALOG POLYMERS

- Expansorb® PLGA, PCL bioresorbable polymers
 - IMPEKK®

Thermoplastic Polymer for 3D-printed implants

• Vitamin E-TPGS - solubility enhancer

A Unique Offer based on 3 Expert R&D Centers for Lipids and Polymers

BOSTON'LAB

Small molecules Lipids & poly-



- 1,000 M² lab-floor
- 5 Kilo Labs
- 1 Pilot Plant
- 30 Scientists with > 50% PhD

ARAMON'LAB

Drug Delivery Polymers



- DDS Polymers dedicated R&D team
- 2 kilolab suites (1 for melt polymerisation)
- 7 scientists with > 50% PhD

SEQENS'Lab

omall molecules Lipids & polymers



- 4 kilo-labs
- 2 cGMP pilot plants with 11 multipurpose reactors (total capacity of 12 m³)
- 110 Scientists with > 50% PhD
- More than 25-Years Track-record in organic, polymers and lipids chemistry
- Double-sourcing offer with lipid and polymer workshops in EU and US
- In-house development and GMP scale-up capacities for lipids and polymers from kilo lab to big industrial scales
- Full regulatory support (IMPD, DMF Filing)

Our commitment is to support our customers in reaching the highest requirements in terms of ingredients performances, selectivity and quality. Our services allow to accelerate the development projects, deliver the products at all stages of the product life cycle, fine-tune the chemical structure, and create opportunities for IP generation.

Custom Lipids

With a recognized **10 years-experience** in **Custom Lipids development and manufacturing**, Seqens has the ability to serve customers with **cationic/ionizable lipids**, **PEG-lipids**, **phospholipids and derivatives**.

Our Custom Lipids offer

CUSTOM LIPID INTERMEDIATES

Leveraging Seqens worldwide non-GMP Assets

Up to multi-tons scale

CUSTOM LIPIDS CGMP

Synthesis and Purification Capabilities (Chromatography, Salt Screening) in the US and EU

Supply from grams to hundreds of kilograms to support from preclinical to commercial phases

TOLLING CAPABILITIES

For **commercial-scale** cGMP Lipid synthesis

Up to multi-tons scale

To serve our customer markets

Sequens answers customers' needs for **Custom Lipids**, which are typically used in **drug delivery systems** to improve the **bioavailability** of drugs:

- Lipid Nanoparticles for mRNA/siRNA/DNA
- Transfection Vectors for Gene Therapies
- Immunotherapies (CAR-T-Cells)
- Lipid prodrugs


- Liposome Vectorization for Oncology, Pain,...
- Lipid-Polymer Hybrid Nanoparticles
- · Cosmetic Lipids

Best-in-class analytical tools

Analytical methods development and GMP validation

Stability studies, Process safety studies Full range of Solid State Analytical tools, incl. XRPD characterization, morphological analysis Impurities
characterization
and Genotoxicity
Assessment (AMES,
in vitro micronucleus test)

Track record and successes



Custom Polymers

Our custom development and manufacturing offer of cGMP polymers to serve our customers' markets

Biodegradable Polymers for Controlled-release

APIs vectorization and Nanocarriers

Solubility / Bioavailability Enhancer

Therapeutic Polymers & Pro-drugs

Polymers
Functionalization &
small molecules
PEG-ylation

Chromatographic Resins Synthesis & Functionalization

Vaccine

Formulation (RNA

Delivery)

Materials for medical devices and Biomedical Implants

Sequens has a High-End Pharma Polymer Expertise Center Covering a Complete Range of Polymerization Technology.


POLYMERS SYNTHESIS

- Ring Opening Polymerizations: PLA/PLGA, PEG/PPG, Polycaprolactone, Glycofurol
- Radical Polymerizations (controlled and uncontrolled)
- Polycondensation: Polyethylenimine,
 Polyamino acids, Polyfumarate copolymers, Polyurea/urethane, Polyacrylic acid, EVA/PVA, Hydrogels
- Block copolymer synthesis
- Sol-Gel Processes
- Lipids, Linkers and APIs PEGylation

POLYMERS MODIFICATION

- Graft Polymerization: Polyvinylpyridine, Polysaccharide, Polysiloxane
- GMP Filtration / Purification
- GMP Lyophilization

Track record and successes



EXPANSORB®

EXPANSORB® GMP PLA & PLGA copolymers are obtained by copolymerization of the corresponding cyclic dimers lactide and glycolide. PLGAs are among the best-in-class functional excipients for controlled-release of injectable drugs, included in multiple commercial formulations, and commonly used material for resorbable medical devices.

Chemical structure

(PLA : n=0) $R_{1} = 0$ $R_{2} = 0$ $R_{2} = 0$ $R_{3} = 0$ $R_{4} = 0$ $R_{2} = 0$ $R_{3} = 0$ $R_{4} = 0$ $R_{5} = 0$ $R_{2} = 0$ $R_{4} = 0$

Chemical Name: poly (lactic acid) / poly (lactic-co-glycolic) acid
Synonym/acronym: PLGA, PLAGA, poly (lactide-co-glycolide)

Properties & applications of GMP-grade PLGA

Properties

- Excellent biocompatibility, controllable biodegradability / bioresorbability
- Highly tunable properties :

LA/GA ratio

Lactide enantiomer ratio (D,L)

Chain length


End-chain

Copolymerization...

Applications

- FDA-approved excipient
- Controlled release formulations (nanoparticles, microparticles)
- Implantable systems for drug delivery
- Resorbable materials for medecine surgery
- Matrix for tissue engineering

Take the control of your drug release!





Seqens Unique Offer

20+ years expertise on PLGA manufacturing within several on-the-market formulations

- Active DMFs i.e. US type IV (Excipients)
- Dedicated onsite R&D capabilities to any fine tuning from lab to industrial scale
- Regulatory services support: IMPD, DMF Filing
- Produced in Europe (Aramon, France)
- GMP compliant (EU, USFDA)
- Classic and ultra-pure Low Monomer and Powder grades available

New! Ultrapure LMP Grade available! With <0,5% monomer content



Ask for our EXPANSORB® catalog

References

A Scalable Manufacturing Approach to Single Dose Vaccination against HPV. *Vaccines*, 2021 (9(1):66), S. Shao, O.A. Ortega-Rivera, S. Ray, J.K. Pokorski, N.F. Steinmetz.

Has PEG-PLGA advantages for the delivery of hydrophobic drugs? Risperidone as an example. Journal of Drug Delivery Science and Technology, 2021 (61), 102239. L. de Souza, R. Eckenstaler, F. Syrowatka, M. Beck-Broichsitter, R. Benndorf, K. Mäder

Novel biodegradable Round Window Disks for inner ear delivery of dexamethasone. *International Journal of Pharmaceutics*, 2021 (594), 120180. E. Lehner, A. Liebau, F. Syrowatka, W. Knolle, S. Plontke, K. Mäder

Apigenin-Loaded PLGA-DMSA Nanoparticles: A Novel Strategy to Treat Melanoma Lung Metastasis. *Molecular Pharmaceutics*, 2021 (March), R. Sen, So. Ganguly, Sh. Ganguly, M. Debnath, S. Chakraborty, B. Mukherjee, D. Chattopadhyay

Vitamin E TPGS

Application field of Vitamin E-TPGS: Pharmaceutical, Nutraceutical, Food and beverage, Cosmetic and Personal Care, Animal nutrition.

Chemical structure

Chemical Name: D-α tocopheryl polyethylene glycol 1000

succinate

Synonym/acronym: TPGS, Tocophersolan, Tocofersolan

$$H^{O}$$

Properties of Vitamin E TPGS

Vitamin E TPGS, a non-ionic surfactant, water soluble derivative of natural Vitamin E, is a multi-role excipient for pharmaceutical drug delivery innovation.

Improving bioavailability



- Absorption enhancer
- PgP inhibitor

Surfactant properties



- Drug solubilizer
- Emulsifier
- Vehicle for lipid based formulation (SEDDS* and SMEDDS**)
- Plasticizer for hot Melt Extrusion
- Stabilizer for
- Amorphous solid
- Dispersion

Source of Vitamin E



- API for Vitamin E (water soluble source of vitamin E)
- Antioxydant

* SEDDS: Self-Emulsifying Drug

Delivery

** SMEDDS: Self-MicroEmulsifying



Type of formulation and administration pathway

Formulation

- Tablet
- Capsule (hard and soft)
- Soft gel
- Solution
- Cream

Administration



- Oral
- Mucosal (buccal, vaginal, nasal etc.)
- Parenteral
- Ophthalmics
- Dermal

Regulatory Status

Active DMFs i.e. US type IV (Excipients)

NF compliant (USP)

Produced in Europe (Germany)

GMP compliance (EU, USFDA)

Physical and chemical properties

Chemical Abstract Index Name

Poly(oxy-1,2-ethanediyl), α -[4-[[(2R)-3,4-dihydro-2,5,7,8-tetramethyl-2-[(4R,8R)-4,8,12-trimethyltridecyl]-2H-1-benzopyran-6-yl]oxy]-1,4-dioxobutyl]- ω -hydroxy-

Empirical Formula: $C_{33}O_5H_{54}(CH_2CH_{20}O)n$


CAS: 9002-96-4

Molecular weight: ~1.5 kDa Melting Point: 36-42 °C

Physical form: waxy solid with low melting point

Color: white to light tan

Vitamin E content (D- α -tocopherol): 25 % minimum weight basis; standard range 25-30 %



IMPEKK®

PEKK produced by Seqens "IMPEKK® polymer" is a high performance thermoplastic designed for permanent surgical implants such as spinal, cranial, orthopedics and dental implants. Its tailored crystallization speed enables IMPEKK® polymer to be perfectly suited for Additive Manufacturing.

Chemical structure of Poly-Ether-Ketone-Ketone (PEKK)


Key properties

The presence of 2 ketone groups compared to other PAEK polymers (Poly-Aryl-Ether-Ketone) gives IMPEKK® polymer greater polarity and allows for better acceptance of functional fillers, providing a wide range of formulation choices for implantable medical device manufacturers. IMPEKK® polymer is composed of ether (flexibilizing) and ketone (rigidifying) groups. The more ketone groups there are, the higher the Tg (Glass Transition temperature) and the better the mechanical properties. IMPEKK® is a copolymer that includes terephthaloyl and isophthaloyl units. This modularity allows fine tuning of crystallization rate and Melting point temperature (Tm).

Terephthaloyl Para linkage

Isophthaloyl Metalinkage

- Elastic modulus close to cortical bone
- X-ray translucency
- Chemical inertness
- Outstanding compressive strength
- High Tg
- Excellent tribological properties
- Excellent barrier properties
- Toughness
- Sterilizable



Applications

Amenable to all polymers processing techniques (Injection Molding/Extrusion): **IMPEKK® 1G-T** (granules for Testing and Development)

	Norm	IMPEKK® 1G-T
Appearance	/	Golden Yellow or White to cream solid
Polymer type	/	Semi-crystalline
Melting range/point (°C)	DSC DIN EN ISO 11357	345-375/358
Glass Transition (°C)	DSC DIN EN ISO 11357	160-170
Tensile test at Break (MPa)	DIN EN ISO 527-1	115
Tensile Modulus (GPa)	DIN EN ISO 527-1	3,7
Impact Strength	DIN EN ISO 179-1eU	180 kJ/m²
Impact Strength (notched)	DIN EN ISO 179-1eA	5,7 kJ/m²
Density	DIN EN ISO 1183	1,30 g/cm³
% Tere/Iso	/	80/20
Crystallization speed	/	Very fast
Processing temperature (°C)	/	385°C
Availability	/	Q3/22

Particularly suited for Additive Manufacturing: **IMPEKK® 3D-F-T** (filaments for Testing and Development)

IMPEKK® 3D can be printed both amorphous and semi-crystalline.


	IMPEKK® 3D-F-T	
Appearance	Golden Yellow or White to cream solid	
Polymer type	Pseudo-amorphous	
Diameter	1,75 mm	
Packaging	500 g spool	
Availability	Available	



PEKK-based Cranial Implant printed by Kumovis



PEKK-based Spinal Cage Implants printed by Kumovis



IMPEKK® 3D-F-T Filament

Contact us: dds@seqens.com

DISCOVER SEQENS PHARMA SOLUTIONS PRODUCTS & SERVICES OFFER



SCAN ME

- Custom manufacturing
- Early stage manufacturing
- Intermediates
- **Drug Delivery Solutions**
- Biocatalysis services

SEQENS

21 Chemin de la sauvegarde CS 33167 69134 Ecully CEDEX TEL. +33 (0) 4 26 99 18 00 www.seqens.com





